

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029

Market Report | 2024-10-03 | 249 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.

?By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period.?

Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.

?Medical device manufacturers segment accounted for the highest CAGR.?

The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.

?Asia Pacific: The fastest-growing region clinical trial imaging market.?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-naïve population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.

The primary interviews conducted for this report can be categorized as follows:

□ By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

□ By Designation: C-level - 27%, D-level - 18%, and Others - 55%

□ By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America ? 6%, and the Middle East & Africa ? 4%

Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Research Coverage:

This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

□ Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.

□ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.

□ Market Development: Comprehensive information about lucrative markets ? the report analyses the clinical trial imaging market across varied regions.

□ Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.

□ Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.

Table of Contents:

1 □ INTRODUCTION □ 30

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.1	STUDY OBJECTIVES	30
1.2	MARKET DEFINITION	30
1.3	STUDY SCOPE	31
1.3.1	SEGMENTS CONSIDERED	31
1.3.2	INCLUSIONS AND EXCLUSIONS	32
1.3.3	YEARS CONSIDERED	32
1.3.4	CURRENCY CONSIDERED	32
1.4	STAKEHOLDERS	33
1.5	SUMMARY OF CHANGES	33
2	RESEARCH METHODOLOGY	34
2.1	RESEARCH DATA	34
2.2	RESEARCH APPROACH	34
2.2.1	SECONDARY DATA	35
2.2.1.1	Key data from secondary sources	35
2.2.1.2	Objectives of secondary research	35
2.2.2	PRIMARY DATA	36
2.2.2.1	Objectives of primary research	36
2.2.2.2	Key data from primary sources	37
2.2.2.3	Key industry insights	38
2.2.2.4	Breakdown of primaries	38
2.3	MARKET SIZE ESTIMATION	39
2.3.1	BOTTOM-UP APPROACH	39
2.3.1.1	Company revenue estimation approach	40
2.3.1.2	Company presentations and primary interviews	40
2.3.1.3	Growth forecasts	40
2.3.1.4	CAGR projections	41
2.3.2	TOP-DOWN APPROACH	41
2.4	DATA TRIANGULATION	42
2.5	STUDY ASSUMPTIONS	43
2.6	RESEARCH LIMITATIONS	43
2.7	RISK ASSESSMENT	44
3	EXECUTIVE SUMMARY	45
?		
4	PREMIUM INSIGHTS	49
4.1	CLINICAL TRIAL IMAGING MARKET OVERVIEW	49
4.2	CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029	49
4.3	CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029	50
4.4	CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029	50
4.5	CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029	51
4.6	CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES	51
5	MARKET OVERVIEW	52
5.1	INTRODUCTION	52
5.2	MARKET DYNAMICS	52
5.2.1	DRIVERS	52
5.2.1.1	Increasing R&D spending in pharmaceutical and biotechnology companies	52
5.2.1.2	Rising number of clinical trials in medical research	53
5.2.1.3	Growth in pharmaceutical and biotechnology industries	54

5.2.1.4	Increasing number of contract research organizations	54
5.2.2	RESTRAINTS	54
5.2.2.1	High implementation cost of imaging systems	54
5.2.3	OPPORTUNITIES	55
5.2.3.1	Growth opportunities in emerging economies	55
5.2.3.2	Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals	55
5.2.4	CHALLENGES	55
5.2.4.1	High cost of clinical trials	55
5.3	PRICING ANALYSIS	56
5.3.1	INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021?2023	56
5.4	PATENT ANALYSIS	57
5.4.1	LIST OF MAJOR PATENTS, 2022?2023	57
5.5	TRADE ANALYSIS	58
5.5.1	TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)	58
5.5.1.1	Import data for X-ray apparatus	58
5.5.1.2	Export data for X-ray apparatus	59
5.5.2	TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)	59
5.5.2.1	Import data for CT apparatus	59
5.5.2.2	Export data for CT apparatus	60
5.6	VALUE CHAIN ANALYSIS	60
5.7	SUPPLY CHAIN ANALYSIS	61
5.8	ECOSYSTEM ANALYSIS	62
5.8.1	ROLE IN ECOSYSTEM	62
?		
5.9	PORTER'S FIVE FORCES ANALYSIS	63
5.9.1	THREAT OF NEW ENTRANTS	64
5.9.2	THREAT OF SUBSTITUTES	64
5.9.3	BARGAINING POWER OF BUYERS	64
5.9.4	BARGAINING POWER OF SUPPLIERS	64
5.9.5	INTENSITY OF COMPETITIVE RIVALRY	65
5.10	KEY STAKEHOLDERS AND BUYING CRITERIA	65
5.10.1	KEY STAKEHOLDERS IN BUYING PROCESS	65
5.10.2	KEY BUYING CRITERIA	66
5.11	REGULATORY ANALYSIS	67
5.11.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	67
5.12	KEY CONFERENCES AND EVENTS IN 2023?2024	71
5.13	TECHNOLOGY ANALYSIS	72
5.13.1	KEY TECHNOLOGIES	72
5.13.1.1	CT and MRI	72
5.13.2	COMPLEMENTARY TECHNOLOGIES	72
5.13.2.1	Ultrasound	72
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	73
5.15	CASE STUDY ANALYSIS	73
5.15.1	REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA	73
5.16	IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET	74
6	CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE	76
6.1	INTRODUCTION	77

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2	SERVICES	77
6.2.1	OPERATIONAL IMAGING SERVICES	79
6.2.1.1	Rising number of CROs and growing pharmaceutical industry to drive market	79
6.2.2	READ ANALYSIS SERVICES	81
6.2.2.1	Increasing number of clinical trials and rising R&D spending to support market growth	81
6.2.3	SYSTEM AND TECHNICAL SUPPORT SERVICES	83
6.2.3.1	Need for continuous technical support to propel segment growth	83
6.2.4	TRIAL DESIGN AND CONSULTING SERVICES	85
6.2.4.1	High R&D spending and favorable government initiatives for clinical trials to fuel market growth	85
6.3	SOFTWARE	87
6.3.1	NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH	87
7	CLINICAL TRIAL IMAGING MARKET, BY MODALITY	90
7.1	INTRODUCTION	91
7.2	COMPUTED TOMOGRAPHY	91
7.2.1	HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH	91
7.3	MAGNETIC RESONANCE IMAGING	94
7.3.1	GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH	94
7.4	ULTRASOUND	96
7.4.1	COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH	96
7.5	POSITRON EMISSION TOMOGRAPHY	99
7.5.1	ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH	99
7.6	X-RAY	101
7.6.1	LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH	101
7.7	OTHER MODALITIES	103
8	CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA	106
8.1	INTRODUCTION	107
8.2	ONCOLOGY	107
8.2.1	GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH	107
8.3	INFECTIOUS DISEASES	110
8.3.1	RIISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH	110
8.4	NEUROLOGY	112
8.4.1	HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH	112
8.5	CARDIOVASCULAR SYSTEM DISORDERS	114
8.5.1	HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH	114
8.6	ENDOCRINOLOGY	116
8.6.1	RIISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET	116
8.7	IMMUNOLOGICAL DISORDERS	119
8.7.1	WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH	119
8.8	OTHER THERAPEUTIC AREAS	121
9	CLINICAL TRIAL IMAGING MARKET, BY END USER	124
9.1	INTRODUCTION	125
9.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	125
9.2.1	HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH	125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.3	MEDICAL DEVICE MANUFACTURERS	129
9.3.1	HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH	129
9.4	CONTRACT RESEARCH ORGANIZATIONS	131
9.4.1	INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH	131
9.5	ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES	134
9.5.1	RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH	134
9.6	OTHER END USERS	136
10	CLINICAL TRIAL IMAGING MARKET, BY REGION	139
10.1	INTRODUCTION	140
10.2	NORTH AMERICA	140
10.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	143
10.2.2	US	144
10.2.2.1	US to dominate North American clinical trial imaging market during study period	144
10.2.3	CANADA	147
10.2.3.1	Increase in per capita healthcare spending to augment market growth	147
10.3	EUROPE	149
10.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	152
10.3.2	GERMANY	153
10.3.2.1	Strong medical technology infrastructure and increased funding for biomedical research to augment market growth	153
10.3.3	UK	155
10.3.3.1	Increased R&D investments and high per capita healthcare expenditure to augment market growth	155
10.3.4	FRANCE	157
10.3.4.1	Developed generics market and favorable government healthcare policies to support market growth	157
10.3.5	ITALY	159
10.3.5.1	Increasing number of drug approvals and rising investments in clinical trials to drive market	159
10.3.6	SPAIN	161
10.3.6.1	Increased biologics production and improved healthcare infrastructure to aid market growth	161
10.3.7	REST OF EUROPE	164
?		
10.4	ASIA PACIFIC	167
10.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	170
10.4.2	CHINA	171
10.4.2.1	Favorable government regulations and presence of large target patient population to boost market growth	171
10.4.3	JAPAN	173
10.4.3.1	Increasing geriatric population and rising healthcare expenditure to favor market growth	173
10.4.4	INDIA	176
10.4.4.1	Increased government focus on developing advanced healthcare infrastructure to augment market growth	176
10.4.5	REST OF ASIA PACIFIC	178
10.5	LATIN AMERICA	181
10.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	183
10.5.2	BRAZIL	184
10.5.2.1	Increasing investments in biopharmaceutical research to propel market growth	184
10.5.3	MEXICO	186
10.5.3.1	Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth	186

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.5.4	REST OF LATIN AMERICA	188
10.6	MIDDLE EAST & AFRICA	191
10.6.1	INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET	191
10.6.2	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	193
10.7	GCC COUNTRIES	194
10.7.1	INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH	194
10.7.2	MACROECONOMIC OUTLOOK FOR GCC COUNTRIES	197
11	COMPETITIVE LANDSCAPE	198
11.1	INTRODUCTION	198
11.2	KEY PLAYER STRATEGY/RIGHT TO WIN	198
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET	198
11.3	REVENUE ANALYSIS, 2021-2023	199
11.4	MARKET SHARE ANALYSIS, 2023	200
11.5	COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)	202
11.5.1	STARS	202
11.5.2	EMERGING LEADERS	202
11.5.3	PERVASIVE PLAYERS	202
11.5.4	PARTICIPANTS	202
11.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	203
11.5.5.1	Company footprint	203
11.5.5.2	Service & software footprint	204
11.5.5.3	Therapeutic area footprint	204
11.5.5.4	Region footprint	204
11.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	205
11.6.1	PROGRESSIVE COMPANIES	205
11.6.2	RESPONSIVE COMPANIES	205
11.6.3	DYNAMIC COMPANIES	205
11.6.4	STARTING BLOCKS	205
11.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	206
11.7	COMPANY VALUATION AND FINANCIAL METRICS	207
11.8	COMPETITIVE SCENARIO	208
11.8.1	SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS	208
11.8.2	DEALS	209
12	COMPANY PROFILES	210
12.1	KEY PLAYERS	210
12.1.1	ICON PLC	210
12.1.1.1	Business overview	210
12.1.1.2	Services/Solutions offered	211
12.1.1.3	Recent developments	211
12.1.1.3.1	Solution launches	211
12.1.1.3.2	Deals	212
12.1.1.4	MnM view	212
12.1.1.4.1	Key strengths	212
12.1.1.4.2	Strategic choices	212
12.1.1.4.3	Weaknesses and competitive threats	213
12.1.2	MEDPACE	214

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.2.1	Business overview	214
12.1.2.2	Services/Solutions offered	215
12.1.2.3	MnM view	215
12.1.2.3.1	Key strengths	215
12.1.2.3.2	Strategic choices	215
12.1.2.3.3	Weaknesses and competitive threats	215
?		
12.1.3	CLARIO	216
12.1.3.1	Business overview	216
12.1.3.2	Services/Solutions offered	216
12.1.3.3	Recent developments	217
12.1.3.3.1	Solution launches	217
12.1.3.3.2	Deals	217
12.1.3.4	MnM view	218
12.1.3.4.1	Key strengths	218
12.1.3.4.2	Strategic choices	218
12.1.3.4.3	Weaknesses and competitive threats	218
12.1.4	IXICO PLC	219
12.1.4.1	Business overview	219
12.1.4.2	Services/Solutions offered	220
12.1.4.3	Recent developments	221
12.1.4.3.1	Deals	221
12.1.4.3.2	Other developments	221
12.1.5	RESONANCE HEALTH LTD.	222
12.1.5.1	Business overview	222
12.1.5.2	Services/Solutions offered	223
12.1.5.3	Recent developments	224
12.1.5.3.1	Service launches and regulatory approvals	224
12.1.5.3.2	Deals	224
12.1.6	RADIANT SAGE	225
12.1.6.1	Business overview	225
12.1.6.2	Services/Solutions offered	225
12.1.7	WCG CLINICAL	226
12.1.7.1	Business overview	226
12.1.7.2	Services/Solutions offered	226
12.1.7.3	Recent developments	226
12.1.7.3.1	Deals	226
12.1.8	CARDIOVASCULAR IMAGING TECHNOLOGIES	227
12.1.8.1	Business overview	227
12.1.8.2	Services/Solutions offered	227
12.2	OTHER PLAYERS	228
12.2.1	MEDICAL METRICS, INC.	228
12.2.2	PRISM CLINICAL IMAGING	229
12.2.3	BOSTON IMAGING CORE LAB	230
12.2.4	ANAGRAM 4 CLINICAL TRIALS	231
12.2.5	VOIANT	231
?		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.2.6	CALYX	232
12.2.7	BIOSPECTIVE INC.	233
12.2.8	PROSCAN IMAGING	234
12.2.9	MICRON, INC.	235
12.2.10	IMAGING ENDPOINTS	236
12.2.11	PERSPECTUM	237
12.2.12	PHARMTRACE	237
12.2.13	NAVITAS LIFE SCIENCES	238
12.2.14	MEDIAN TECHNOLOGIES	238
12.2.15	INVICRO, LLC	239
12.2.16	IMAGE CORE LAB	239
12.2.17	IMAGE ANALYSIS GROUP (IAG)	240
13	APPENDIX	241
13.1	DISCUSSION GUIDE	241
13.2	KNOWLEDGESTORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL	245
13.3	CUSTOMIZATION OPTIONS	247
13.4	RELATED REPORTS	247
13.5	AUTHOR DETAILS	248

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029

Market Report | 2024-10-03 | 249 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-07

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com